Goldman analyst Salveen Richter raised the program's probability of success to 75% from 70% following the positive results. The bank is"optimistic on the forward outlook for the vaccine" and expects phase-two trials to begin in the current quarter. Phase-three studies will start in July, Richter estimated.Small companies are the biggest post-coronavirus battleground on Wall Street.
Goldman's new target implies a 25% jump from the stock's price as of 12:25 p.m. ET. The new target surpasses the previous Wall Street high of $83. Moderna shares have more than quadrupled in the year-to-date as the firm races to develop the first coronavirus vaccine. The company hopes to have a vaccine ready for use by the fall, fast-tracking the trial process as global COVID-19 cases continue to soar.Now read more markets coverage from Markets Insider and Business Insider:
Source: Financial Digest (financialdigest.net)
Read that as Madonna...made the headline completely confusing
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks making the biggest moves midday: Moderna, Delta, Bank of America, Best Buy, Disney & moreModerna shares spike on 'positive data' from its coronavirus vaccine trial. Netflix shares slip as investors rotate out of 'stay-at-home' stocks. Of course, the vaccine won’t be available before years but who cares. AMAZING 6 Weeks Weightless and Fitness Coaching and Online Support in UK But today you only pay £99!! Jonny Heywood FB : FB Page: FB Group: Facebook Live Class:
Source: CNBC - 🏆 12. / 72 Read more »
Moderna Reveals ‘Positive’ Data In Coronavirus Vaccine Trial, Markets SpikeBoston biopharmaceutical Moderna announced today that “positive” data was collected from an early-stage human trial of a coronavirus vaccine by lisettevoytko lisettevoytko They always are positive. lisettevoytko lisettevoytko not buying it in February is going to be my biggest 2020 financial regret.
Source: Forbes - 🏆 394. / 53 Read more »
Moderna coronavirus vaccine releases first human trial results - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web. It will be the first product they ever got to market. Nothing out of trials. Nothing FDA approved. Nothing sold yet. Just saying we are getting excited about a company that has never made a pharma product for public use. My body my choice I won't take no shot ahmad_shahzwan habisla degree first sem kena face to face... Aku nak online 😭
Source: BusinessInsider - 🏆 729. / 51 Read more »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people. Promising indeed. But, this is only a Phase I trial. be realistic, early stage ..... just fireworks, to distract the market. tell the truth, the economy must be stopped for a month, people are dying and now children are sick. you will not put, better the truth and stand up again
Source: CNBC - 🏆 12. / 72 Read more »
Stocks rebound as positive Moderna vaccine trial boosts optimism for economic recoveryStocks bounced back Monday on optimism the U.S. economy may start to recover from the coronavirus pandemic after drugmaker Moderna released promising early results for a vaccine. result ?didnt stop the virus ! but didnt kill any rats in the last test
Source: USATODAY - 🏆 100. / 63 Read more »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%. Classic PR stunt... I wonder how many of these pharma companies will mislead us.
Source: MarketWatch - 🏆 3. / 97 Read more »